Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia (INPACT-DEEP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a prospective, multi-center, randomized (2:1) trial of symptomatic patients with critical limb ischemia (CLI) secondary to atherosclerotic lesions (stenotic or occluded) of the infrapopliteal vessels. Patients will undergo a percutaneous transluminal endovascular procedure with either the IN.PACT Amphirion™ drug eluting balloon or with a standard PTA balloon. Patients will be followed with pre-study, post-study, and follow-up evaluations.
| Condition | Intervention |
|---|---|
|
Chronic Critical Limb Ischemia |
Device: IN.PACT Amphirion Device: Standard PTA balloon |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Randomized Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia |
- Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA) [ Time Frame: 12 months or at TLR time ] [ Designated as safety issue: No ]
- Clinically driven TLR of the target lesion in the amputation free surviving patients [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Composite of all cause death, major amputation and clinically driven TLR [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- Amputation free survival [ Time Frame: 30 days, 3 and 6 months, 1, 2, 3, 4 and 5 years ] [ Designated as safety issue: No ]
- Rate of wound healing [ Time Frame: 30 days, 6 months, 1 and 2 years ] [ Designated as safety issue: No ]
- Amputation free survival and wound healing [ Time Frame: 6 months, 1 and 2 years ] [ Designated as safety issue: No ]
- Amputation free survival and resolved CLI [ Time Frame: 6 months, 1 and 2 years ] [ Designated as safety issue: No ]
- Death, amputation and clinically driven TLR [ Time Frame: 30 days, 6 months, 1 and 2 years ] [ Designated as safety issue: Yes ]
- Primary sustained clinical improvement [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Secondary sustained clinical improvement [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Quality of life assessment by EQ5D vs. baseline [ Time Frame: 6 months, 1, and 2 years ] [ Designated as safety issue: No ]
- Walking capacity assessment vs. baseline [ Time Frame: 6 months, 1 and 2 years ] [ Designated as safety issue: No ]
- MAE (Major Adverse Events) [ Time Frame: 30 days, 6 months, 1, 2, 3, 4, 5 years ] [ Designated as safety issue: Yes ]
- Device Success [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
- Technical Success [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
- Procedural Success [ Time Frame: Day 1 ] [ Designated as safety issue: Yes ]
- Days of hospitalization [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
- Improvement % diameter stenosis (%DS) of the TL assessed by Quantitative Vascular Angiography (QVA) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 357 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | August 2017 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Drug Eluting Balloon |
Device: IN.PACT Amphirion
Balloon Angioplasty
Other Name: IN.PACT Amphirion
|
| Active Comparator: standard PTA |
Device: Standard PTA balloon
Balloon Angioplasty
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
General Inclusion Criteria
- Age ≥18 years and ≤85 years
- Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an EC approved consent form
- Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
- Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 4, 5 or 6
- Life expectancy >1 year in the Investigator's opinion
General Angiographic Inclusion Criteria
- Reference vessel(s) diameter between 2 and 4 mm
- Single or multiple lesions with ≥70% DS of different lengths in one or more main afferent crural vessels including the tibioperoneal trunk
- At least one non occluded crural vessel with angiographically documented run-off to the foot either direct or through collaterals
Angiographic Inclusion Criteria for Late Lumen Loss (LLL) assessment
- Angio-TL is one identifiable single solitary or series of multiple adjacent lesions with a DS ≥70% and a cumulative length ≤100 mm that can be covered by a single IN.PACT Amphirion™ (10 mm balloon landing zone in both edges is mandatory)
- Angio-TL is the only lesion in that vessel (only one Angio-TL per patient is allowed)
Exclusion Criteria:
General Exclusion Criteria
- Patient unwilling or unlikely to comply with FU schedule
- Planned major index limb amputation
General Angiographic Exclusion Criteria
- Lesion and / or occlusions located or extending in the popliteal artery or below the ankle joint space
- Inflow lesion or occlusion in the ipsilateral Iliac, SFA, popliteal arteries with length ≥15 cm
- Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral Iliac, SFA and popliteal arteries left untreated
- Previously implanted stent in the TL(s)
- Aneurysm in the target vessel
- Acute thrombus in the target limb
General Procedural Exclusion Criteria
- Failure to obtain a <30% residual stenosis in pre-existing, hemodynamically significant (≥50% DS and <15 cm length) inflow lesions in the ipsilateral iliac, SFA and popliteal artery. No Drug Eluting Stents (DES) and / or DEB allowed for the treatment of inflow lesions.
- Failure to cross the TL with a 0.014" guide wire
- Use of alternative therapy, e.g. atherectomy, cutting balloon, laser, radiation therapy, DES as part of the index procedure
ANGIOGRAPHIC cohort General Exclusion Criteria:
- GFR <30 ml/min except for patients with renal end stage disease on chronic haemodialysis
Contacts and Locations| Germany | |
| Herz-Zentrum Bad Krozingen | |
| Bad Krozingen, Germany, 79189 | |
| Park-Krankenhaus Leipzig | |
| Leipzig, Germany, 04289 | |
| Switzerland | |
| University of Bern | |
| Bern, Switzerland, 3010 | |
| Principal Investigator: | Dierk Scheinert, MD | Herzzentrum Leipzig |
| Principal Investigator: | Thomas Zeller, MD | Heart Center Bad Krozingen |
| Principal Investigator: | Iris Baumgartner, MD | University Hospital Inselspital, Berne |
More Information
No publications provided
| Responsible Party: | Medtronic Endovascular |
| ClinicalTrials.gov Identifier: | NCT00941733 History of Changes |
| Other Study ID Numbers: | P998 |
| Study First Received: | July 16, 2009 |
| Last Updated: | January 24, 2013 |
| Health Authority: | Italy: Ethics Committee Germany: Ethics Commission Germany: German Institute of Medical Documentation and Information Belgium: Institutional Review Board Austria: Ethikkommission Switzerland: Ethikkommission The Netherlands: Independent Ethics Committee |
Keywords provided by Medtronic Endovascular:
|
BTK CLI PTA |
Additional relevant MeSH terms:
|
Ischemia Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013